A 2022 Systematic Review and Meta-Analysis of Enriched Therapeutic Diets and Nutraceuticals in Canine and Feline Osteoarthritis
- PMID: 36142319
- PMCID: PMC9499673
- DOI: 10.3390/ijms231810384
A 2022 Systematic Review and Meta-Analysis of Enriched Therapeutic Diets and Nutraceuticals in Canine and Feline Osteoarthritis
Abstract
With osteoarthritis being the most common degenerative disease in pet animals, a very broad panel of natural health products is available on the market for its management. The aim of this systematic review and meta-analysis, registered on PROSPERO (CRD42021279368), was to test for the evidence of clinical analgesia efficacy of fortified foods and nutraceuticals administered in dogs and cats affected by osteoarthritis. In four electronic bibliographic databases, 1578 publications were retrieved plus 20 additional publications from internal sources. Fifty-seven articles were included, comprising 72 trials divided into nine different categories of natural health compound. The efficacy assessment, associated to the level of quality of each trial, presented an evident clinical analgesic efficacy for omega-3-enriched diets, omega-3 supplements and cannabidiol (to a lesser degree). Our analyses showed a weak efficacy of collagen and a very marked non-effect of chondroitin-glucosamine nutraceuticals, which leads us to recommend that the latter products should no longer be recommended for pain management in canine and feline osteoarthritis.
Keywords: animal; enriched diets; methodological quality; metrological validation; nutraceuticals; osteoarthritis; pain; scientific evidence.
Conflict of interest statement
The authors report having conducted work in canine osteoarthritis for the following companies: Biotanika, Inc; Boehringer-Ingelheim Animal Health, Inc; Centrexion Therapeutics, Corp; Ceva Santé Animale, S.A.; Elanco, Ltd.; Intervet, Corp; Merck Animal Health, Inc; Midwest Health Technologies, L.L.C.; Nestlé Purina Petcare, S.A.; Royal-Canin, Inc, a division of Mars Petcare; Vétoquinol, S.A.; Vita Green Health Products Co, Ltd.; and Zoetis, L.L.C.; many of which have led to publications that are included in this systematic review and meta-analysis. The authors declare no conflict of interest directly related to the conduct of this review.
Figures
![Figure 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/9499673/bin/ijms-23-10384-g001.gif)
![Figure 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/9499673/bin/ijms-23-10384-g002.gif)
![Figure 3](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/9499673/bin/ijms-23-10384-g003.gif)
![Figure 4](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/9499673/bin/ijms-23-10384-g004.gif)
Similar articles
-
Comparison of meloxicam and a glucosamine-chondroitin supplement in management of feline osteoarthritis. A double-blind randomised, placebo-controlled, prospective trial.Vet Comp Orthop Traumatol. 2014;27(1):20-6. doi: 10.3415/VCOT-12-11-0139. Epub 2013 Oct 22. Vet Comp Orthop Traumatol. 2014. PMID: 24146058 Clinical Trial.
-
Systematic review of efficacy of nutraceuticals to alleviate clinical signs of osteoarthritis.J Vet Intern Med. 2012 May-Jun;26(3):448-56. doi: 10.1111/j.1939-1676.2012.00901.x. Epub 2012 Mar 9. J Vet Intern Med. 2012. PMID: 22404506 Review.
-
Nutraceuticals as therapeutic agents in osteoarthritis. The role of glucosamine, chondroitin sulfate, and collagen hydrolysate.Rheum Dis Clin North Am. 1999 May;25(2):379-95. doi: 10.1016/s0889-857x(05)70074-0. Rheum Dis Clin North Am. 1999. PMID: 10356424 Review.
-
Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis.JAMA. 2000 Mar 15;283(11):1469-75. doi: 10.1001/jama.283.11.1469. JAMA. 2000. PMID: 10732937 Review.
-
Systematic review of clinical trials of treatments for osteoarthritis in dogs.J Am Vet Med Assoc. 2007 Feb 15;230(4):514-21. doi: 10.2460/javma.230.4.514. J Am Vet Med Assoc. 2007. PMID: 17302547 Review.
Cited by
-
Concurrent Validation of MI-CAT(V), a Clinical Metrology Instrument for Veterinarians Assessing Osteoarthritis Pain in Cats, through Testing for Firocoxib Analgesic Efficacy in a Prospective, Randomized, Controlled, and Blinded Study.Animals (Basel). 2024 Feb 24;14(5):711. doi: 10.3390/ani14050711. Animals (Basel). 2024. PMID: 38473097 Free PMC article.
-
Thai veterinarians' perceptions of cannabidiol products for dogs with osteoarthritis: a qualitative interview study.Front Vet Sci. 2023 Dec 14;10:1304180. doi: 10.3389/fvets.2023.1304180. eCollection 2023. Front Vet Sci. 2023. PMID: 38162477 Free PMC article.
-
Efficacy and safety of cannabidiol for the treatment of canine osteoarthritis: a systematic review and meta-analysis of animal intervention studies.Front Vet Sci. 2023 Sep 15;10:1248417. doi: 10.3389/fvets.2023.1248417. eCollection 2023. Front Vet Sci. 2023. PMID: 37781283 Free PMC article.
-
Therapeutic efficacy and pharmacokinetics of liposomal-cannabidiol injection: a pilot clinical study in dogs with naturally-occurring osteoarthritis.Front Vet Sci. 2023 Aug 23;10:1224452. doi: 10.3389/fvets.2023.1224452. eCollection 2023. Front Vet Sci. 2023. PMID: 37680386 Free PMC article.
-
Research of Pathogenesis and Novel Therapeutics in Arthritis 3.0.Int J Mol Sci. 2023 Jun 15;24(12):10166. doi: 10.3390/ijms241210166. Int J Mol Sci. 2023. PMID: 37373313 Free PMC article.
References
-
- Shearer P. Epidemiology of orthopedic disease. In: McNeill E., editor. Orthopedic Conditions in Cats and Dogs. Volume 21. Royal Canin; Aimargues, France: 2011. pp. 24–25.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous